Edition:
India

Ablynx NV (ABLX.OQ)

ABLX.OQ on NASDAQ Stock Exchange Global Select Market

22.80USD
24 Nov 2017
Change (% chg)

$-0.74 (-3.14%)
Prev Close
$23.54
Open
$23.10
Day's High
$23.15
Day's Low
$22.71
Volume
33,338
Avg. Vol
--
52-wk High
$23.63
52-wk Low
$17.75

Chart for

About

Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and... (more)

Overall

Beta: 1.59
Market Cap(Mil.): €987.62
Shares Outstanding(Mil.): 61.42
Dividend: --
Yield (%): --

Financials

BRIEF-Ablynx 9-month revenues decrease to 44.7 million euros ​

* 9 MONTH REVENUES OF EUR 44.7 MILLION (2016: EUR 68.9 MILLION)​

16 Nov 2017

BRIEF-Ablynx announces full exercise of underwriters' option to purchase additional shares

* ABLYNX ANNOUNCES FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES AND END OF STABILIZATION PERIOD

27 Oct 2017

BRIEF-Ablynx prices $200 mln IPO in the United States

* Ablynx prices $200 million initial public offering in the United States

25 Oct 2017

BRIEF-Ablynx NV now sees IPO of up to 9.5 mln ordinary shares

* Ablynx NV now sees IPO of up to 9.5 million ordinary shares including 8.1 million ordinary shares in form of American Depositary Shares - sec filing

24 Oct 2017

BRIEF-Ablynx NV offers 9.2 million of its ordinary shares in global offering

* Ablynx NV sees offering of 9.2 million of its ordinary shares in a global offering - SEC filing

20 Oct 2017

BRIEF-Ablynx to offer and sell about $175 million of its ordinary shares

* ‍INTENDS TO OFFER AND SELL ABOUT $175 MILLION OF ITS ORDINARY SHARES IN A GLOBAL OFFERING​

17 Oct 2017

BRIEF-Ablynx establishes subsidiary in USA

* ABLYNX ESTABLISHES SUBSIDIARY IN THE USA AND APPOINTS A GENERAL MANAGER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

16 Oct 2017

BRIEF-Ablynx NV files for U.S. IPO of up to $150 mln

* Ablynx NV files for U.S. IPO of up to $150.0 million ‍- SEC filing‍​

03 Oct 2017

Belgian biotech Ablynx scores big hit with blood disease drug

Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder on Monday, sending its market value above $1.1 billion.

02 Oct 2017

BRIEF-Ablynx announces positive topline results of Phase III Hercules study of Caplacizumab

* ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP

02 Oct 2017

Earnings vs. Estimates